Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 2, 2008, Pages 484-490

  Reddy, L Harivardhan ^a   Marque, Pierre Emmanuel ^b   Dubernet, Catherine ^a   Mouelhi, Sinda Lepêtre ^a   Desmaële, Didier ^a   Couvreur, Patrick ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b Medsqual   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; GEMCITABINE; SQUALENE; DEOXYCYTIDINE; DRUG DERIVATIVE; NANOMATERIAL;

ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD ANALYSIS; BLOOD TOXICITY; CANCER SURVIVOR; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG SAFETY; DRUG SYNTHESIS; GASTROINTESTINAL TOXICITY; LEUKEMIA; LIVER TOXICITY; MORTALITY; MOUSE; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION; ANIMAL; CHEMISTRY; COMPARATIVE STUDY; DBA MOUSE; DRUG SCREENING; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTARABINE; DEOXYCYTIDINE; DRUG EVALUATION, PRECLINICAL; LEUKEMIA; MICE; MICE, INBRED DBA; NANOMEDICINE; NANOSTRUCTURES; SQUALENE; TREATMENT OUTCOME;

EID: 42449100440     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.133751     Document Type: Article

References (15)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al. (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 3:491-498.
2. Angiolillo AL, Whitlock J, Chen MS, Krailo M, and Reaman G (2006) Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a children's oncology group report. Pediatr Blood Cancer 46:193-197.
3. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, and Peters GJ (1995) Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 22:42-46.
4. Couvreur P, Stella B, Cattel L, Rocco F, Renoir J-M, and Rosilio V (2006a), inventors; Universite Paris-Sud XI, Universita degli Studi di Torino, Couvreur P, Stella B, Cattel L, Rocco F, Renoir J-M, and Rosilio V, assignees. Gemcitabine derivatives nanoparticles. World Patent 2006/090029. 2006 Aug 31.
5. Couvreur P, Stella B, Reddy LH, Hillaireau H, Dubernet C, Desmaële D, Lepêtre-Mouelhi S, Rocco F, Dereuddre-Bosquet N, Clayette P, et al. (2006b) Squalenoyl nanomedicines as potential therapeutics. Nano Lett 6:2544-2548.
6. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, and Plunkett W (1990) Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 50:6823-6826.
7. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, and Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50:4417-4422.
8. Ojo-Amaize EA, Cottam HB, Oyemade OA, Okogun JI, and Nchekwube EJ (2007) Hypoestoxide inhibits tumor growth in the mouse CT26 colon tumor model. World J Gastroenterol 13:4586-4588.
9. Ravindranath Y (2003) Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr Opin Oncol 15:23-35.
10. Reddy LH, Dubernet C, Lepêtre-Mouelhi S, Desmaële D, and Couvreur P (2007) A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types. J Control Release 124:20-27.
11. Ribera JM and Oroil A (2007) A step forward in therapy for ALL in infants. Lancet 370:198-200.
12. Robinson K, Lambiase L, Li J, Monteiro C, and Schiff M (2003) Fatal cholestatic liver failure associated with gemcitabine therapy. Dig Dis Sci 48:1804-1808.
13. Roboz GJ (2007) Treatment of acute myeloid leukemia in older patients. Expert Rev Anticancer Ther 7:285-295.
14. Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, and Abbruzzese J (2003) Randomized phase II comparison of dose intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402-3408.
15. Wagner-Bohn A, Henze G, von Stackelberg A, and Boos J (2006) Phase II study of gemcitabine in children with relapsed leukemia. Pediatr Blood Cancer 46:262.